Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Capital Equipment E-Procurement Will Trail Med/Surg Product Sales - GPOs

This article was originally published in The Gray Sheet

Executive Summary

The size of the transactions involved in capital equipment sales over the Internet will cause the volume of such deals to lag behind e-procurement of med/surg supplies and disposable products, group purchasing organization execs said April 3.

You may also be interested in...



Clinical Process Approach To Product Development Urged By GPO Chief

Value-added service, standardization of care, and cost efficiency factors need to be incorporated into medical device product development to temper GPO members' penchant for unit price reduction, according to Premier.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014707

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel